Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms MARINER
- Sponsors Janssen Research & Development; Janssen-Cilag
- 23 May 2017 This trial has been completed in Slovakia.
- 08 May 2017 Planned End Date changed from 9 May 2018 to 25 May 2018.
- 08 May 2017 Planned primary completion date changed from 22 Feb 2018 to 25 May 2018.